In addition, we also found the prognostic difference between the MYL5 high-expression group and the low-expression group among colorectal cancer, soft tissue cancer, acute myelocytic leukemia (AML), and multiple myeloma (MM). This evidence concerns the gene MYL5 and Miyoshi myopathy.